RESEARCH, EXPLAINED
Research updates and source-led explainers, organised by peptide, health topic and date.
For longer articles connecting several findings, explore Features →
Explore by topic: Longevity & Healthy Ageing
46 articles · Newest published first
Publication dates refer to Her Own Way articles. Original study or source dates are shown separately.
Try another topic or clear your filters. Articles appear here as they are published.
Browse the fact sheets ↗Combining amylin with tirzepatide produced a big weight-loss result. I want the story to include the people who could not continue treatment too.
Source context: Lilly announcement and EASD presentation · 30 September 2026
Published · Updated
Read article : EloraTZP: What the 23.3% Weight-Loss Headline Leaves OutThe biggest weight-loss number is not the only thing I care about. Petrelintide raises a useful question about how manageable future treatments might be.
Source context: ZUPREME-1 publication and EASD reporting · 29–30 September 2026
Published · Updated
Read article : Could the Next Weight-Loss Peptide Be Gentler? Petrelintide and the Tolerability QuestionThe weight-loss and diabetes-remission results are striking. I want to understand exactly what they mean, especially when “remission” can sound like “cure”.
Source context: REDEFINE 1 (2025); REIMAGINE 1 (2026); review 28 September 2026
Published · Updated
Read article : Cagrilintide and CagriSema: Weight Loss and What Remission MeansAmycretin now has a new name: zenagamtide. I look at the study behind the big weight-loss headline and why the details need to travel with it.
Source context: The Lancet · June 2025 and July 2026; review September 2026
Published · Updated
Read article : Zenagamtide, Formerly Amycretin: Behind the 24.3% HeadlineAmylin is opening a different conversation about weight treatment. I look at what eloralintide did in this trial, and what I would still want to know about living with it.
Source context: The Lancet and Lilly · November 2025
Published · Updated
Read article : Eloralintide: What the 48-Week Amylin Trial FoundWhat might weight treatment mean for muscle and sleep after menopause? I look at a review that brings those questions together without claiming they are all answered.
Source context: Maturitas · 14 September 2026 online
Published · Updated
Read article : Semaglutide After Menopause: A Review of Muscle and Sleep QuestionsA scan study raises another question about muscle during treatment. I explain why it is worth watching without treating an early finding as a prediction for you.
Source context: medRxiv · posted 17 September 2026
Published · Updated
Read article : GLP-1 Medicines and Muscle: Reading the New MRI PreprintI want midlife treatment conversations to include muscle, bones and nourishment as well as weight. This expert statement asks those questions, while acknowledging the evidence gaps.
Source context: Spanish Menopause Society · Maturitas · 25 August 2026 online
Published · Updated
Read article : Incretin Medicines at Menopause: What the New Position Statement SaysCould weight treatment help breathing during sleep? I look at what these trials found, while keeping sleep apnoea separate from other reasons for a difficult night.
Source context: New England Journal of Medicine · 21 June 2024 online
Published · Updated
Read article : Sleep Apnoea and Weight Treatment: What SURMOUNT-OSA TestedWhen weight comes off, what else changes? I look at the STEP 1 findings on fat and lean mass, and why they do not tell us everything about strength.
Source context: Journal of the Endocrine Society · 2021
Published · Updated
Read article : Semaglutide and Body Composition: What STEP 1 MeasuredThe label said retatrutide. Australian testing found something else. This is why I keep the research and the contents of a purchased vial separate.
Source context: TGA safety advisory · 14 September 2026
Published · Updated
Read article : Buying “Retatrutide” Online? Australian Testing Found Something Very Different in the VialWhy is MOTS-c called an “exercise peptide”? I look at the research behind the name and the difference between measuring it after exercise and taking it as a treatment.
Source context: Reynolds and colleagues · Nature Communications · 20 January 2021
Published · Updated
Read article : MOTS-c: What the “Exercise Peptide” Research Actually Shows“Switching on” a cell pathway sounds promising. I want to know whether the repair researchers hoped for actually followed — and this study complicates the picture.
Source context: Xing and colleagues · Inflammation and Regeneration · 22 June 2026
Published · Updated
Read article : MOTS-c and Cellular Repair: Why Switching On a Pathway Isn’t the Whole StoryThis MOTS-c study included women, which makes it especially worth reading carefully. The important detail is that they exercised — they were not given the peptide.
Source context: Dieli-Conwright and colleagues · Scientific Reports · 19 August 2021
Published · Updated
Read article : Exercise and MOTS-c: What a Study in Women FoundA menopause-related MOTS-c headline can sound very relevant to women’s lives. I look at what the mouse study found and what it cannot yet tell us.
Source context: Lu and colleagues · Journal of Molecular Medicine · online 6 February 2019; April 2019 issue
Published · Updated
Read article : MOTS-c and Menopause: What a Mouse Study Can—and Cannot—Tell UsNAD+, NMN, NR: the names can blur together quickly. Here is how I make sense of them, starting with what the product says it contains.
Source context: Therapeutic Goods Administration guidance · 12 August 2026
Published · Updated
Read article : NAD+, NMN and NR: What’s the Difference—and What Is Actually in the Bottle?A blood measurement went up. But did anyone feel better? That is the distinction I want to understand before a laboratory result becomes a wellbeing promise.
Source context: Kornilov and colleagues · GeroScience · 30 July 2026
Published · Updated
Read article : An Oral NAD+ Trial Raised a Blood Marker—But Did People Feel Better?A study can be real without proving the claim attached to it. I look at what this often-mentioned NAD+ infusion study actually asked about recovery.
Source context: Grant and colleagues · Frontiers in Aging Neuroscience · 12 September 2019
Published · Updated
Read article : NAD+ and Addiction Recovery: What Does the IV Research Actually Test?When you are less hungry, “eat less” stops being a useful answer. I look at nourishment, strength and what to ask when food feels difficult.
Source context: Obesity Medicine Association explainer · 1 August 2026 · Joint expert advisory · 2025
Published · Updated
Read article : Less Hungry Doesn’t Mean Less Nourishment: Eating Well on GLP-1 MedicinesA headline about the menopausal brain can sound frightening. I want to understand what the scans show without turning them into a prediction about you.
Source context: Nature Communications · 8 September 2026
Published · Updated
Read article : Your Brain at Menopause: Change Does Not Automatically Mean DeclineIf migraine keeps arriving around your period, could prevention focus on that window? I look at a new trial and what its result might mean in everyday terms.
Source context: AbbVie LUNA announcement · 10 September 2026
Published · Updated
Read article : Could Migraine Prevention Be Timed to Your Period?Migraine has been part of my life since my teens. This is about the extra burden of explaining pain other people cannot see, and making room for support.
Source context: The Migraine Trust, Unbelievable report coverage · 21 September 2026
Published · Updated
Read article : Migraine Is Hard Enough Without Having to Prove You’re Unwell“Get more rest” can feel like very small advice for a very big problem. I look at how sleep and migraine interact, without making another thing to blame yourself for.
Source context: The Migraine Trust researcher explainer · 26 August 2026
Published · Updated
Read article : Migraine and Sleep: Why “Just Get More Rest” Isn’t the Whole AnswerA diagnosis can make ordinary movement feel uncertain. I want to understand what helps women keep moving with support, rather than feeling they have to guess.
Source context: Frontiers in Physiology · 12 August 2026 · Healthy Bones Australia guidance · 27 November 2023
Published · Updated
Read article : Low Bone Density Doesn’t Mean You Have to Stop MovingIf the scales barely move, it is easy to wonder whether your effort counts. I want us to notice other changes that matter to health and everyday life.
Source context: Frontiers in Medicine · 12 August 2026
Published · Updated
Read article : Exercise After Menopause: Benefits the Scales Won’t Show YouWhen even getting started feels hard, I do not think exercise should become another test of willpower. This small study asks a more inviting question.
Source context: University of Limerick research-team summary · 17 July 2026 (summary publication date)
Published · Updated
Read article : You Don’t Have to Lift Heavy to Start: Strength Training, Low Mood and the First StepA headline about hormones and Alzheimer’s can make a personal decision feel urgent. I want to slow it down and look at what the study can really tell us.
Source context: Neurology · online 12 August 2026; issue 8 September 2026 · NICE guidance checked 26 September 2026
Published · Updated
Read article : Does HRT Protect the Brain? Why One New Study Cannot Settle the QuestionCould a blood sample help researchers understand menopause and the brain? I am curious about the possibility, but a research clue is not a prediction of your future.
Source context: Nature Medicine · 22 September 2026
Published · Updated
Read article : Could Menopause Leave a Signature in Our Blood?My diagnosis helped me understand my own life. This review made me ask whether the research is answering enough of the questions women bring with them.
Source context: Journal of Attention Disorders · 21 July 2026 · Research published 1989–2024; abstract reviewed
Published · Updated
Read article : ADHD in Women: What Research Is Finally Asking—and What It Still MissesADHD and digestive symptoms can turn up in the same life. I look at the connection without assuming one explains the other, or that a gut treatment can cure ADHD.
Source context: Journal of Attention Disorders · 10 September 2026
Published · Updated
Read article : ADHD and Gut Symptoms: Is There a Connection?Trying to work out who can help with ADHD can feel like another task in itself. Here are the questions I would use to make that first phone call clearer.
Source context: NSW Agency for Clinical Innovation FAQs · September 2026 version
Published · Updated
Read article : Can My GP Diagnose or Prescribe for ADHD? What NSW Women Need to KnowA small trial raises the possibility of another option for people wanting to change their drinking. I look at the hopeful finding and the difficult parts together.
Source context: Altimmune RECLAIM announcement · 28 July 2026
Published · Updated
Read article : Could a Metabolic Medicine Help Reduce Heavy Drinking?A conversation about drinking may need to include other substances too. I look at what one survey found and why honesty should lead to better support.
Source context: JAMA Network Open · 24 September 2026 · US survey data from 2021–2024
Published · Updated
Read article : Alcohol and Cannabis Together: The Overlap We Don’t Always Talk AboutSometimes the question is simply whether an evening habit still feels right for you. I want to make space for that conversation without judgement.
Source context: Keck Medicine of USC · 21 September 2026 · Summary of research in Annals of Internal Medicine
Published · Updated
Read article : Midlife Drinking Deserves Its Own ConversationWhen a headline says one medicine is “better”, I want to know what was actually compared — and what that might mean for the person taking it.
Source context: Novo Nordisk REIMAGINE-5 announcement · 21 September 2026
Published · Updated
Read article : Did CagriSema Really Beat Mounjaro? Why the Comparison MattersYou can be pleased with changes in your health and still be upset about your hair. I want there to be room for both in the treatment conversation.
Source context: The BMJ · 22 July 2026 · Study findings checked against the PubMed abstract
Published · Updated
Read article : Hair Loss on GLP-1 Medicines: A Side Effect Worth Taking SeriouslyI want to know what sits behind a striking weight-loss number. The fuller TRIUMPH-2 results give us more to talk about, including side effects and unanswered questions.
Source context: TRIUMPH-2: The Lancet · 29 September 2026; TRIUMPH-3: July sponsor report
Published · Updated
Read article : Retatrutide’s Phase 3 Evidence Has Matured: What TRIUMPH-2 Now Tells UsFor me, feeling well means having the energy to enjoy life. I want our fitness conversations to make room for that, alongside rest, setbacks and starting again.
Source context: Editorial context
Published · Updated
Read article : Fitness, strength & feeling like yourselfCould medicines being studied for metabolic health also help with drinking? I want to follow that question without reducing recovery to a medicine.
Source context: Clinical trials · 2025–2026
Published · Updated
Read article : Alcohol, cravings & recoveryHaving lived with migraine, I understand why a new possibility gets our attention. Here is the small study that made me curious, and where its answers stop.
Source context: Pilot study · 2025
Published · Updated
Read article : Migraine & the peptide connectionI noticed changes I had not gone looking for. That made me curious about focus and food noise, while leaving plenty of questions about what caused them.
Source context: Australian regulatory guidance
Published · Updated
Read article : Focus, ADHD & “food noise”The research now goes beyond the early weight-loss headlines. I unpack what TRIUMPH-1 adds and why different numbers can describe different things.
Source context: NEJM · 29 September 2026; Lilly news release · 6 June 2026
Published · Updated
Read article : Retatrutide TRIUMPH-1: the published Phase 3 evidence beyond the headlineThe 24.2% result caught plenty of attention. Here is what I take from the original trial, alongside the side effects and questions it could not answer.
Source context: NEJM · 2023
Published · Updated
Read article : Retatrutide for obesity — NEJM, 2023If the medicine names and hormone talk feel like a lot, start here. I look at what these treatments do and why the differences matter.
Source context: Australian regulatory guidance
Published · Updated
Read article : Weight, insulin & GLP-1 medicinesWeight, sleep, concentration and migraine can all become part of the midlife conversation. I want us to have room to talk about the whole picture.
Source context: Clinical guidance and a 2025 study
Published · Updated
Read article : Perimenopause & menopause: joining the dotsRetatrutide has produced some of the biggest weight-loss numbers we’ve seen in clinical trials. But I’m just as interested in what researchers are finding beyond the scales — and what we still don’t know.
Source context: Research and guidance · 2023–2026
Published · Updated
Read article : Retatrutide: Looking Beyond the Weight-Loss Headlines